The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future.

Diagnostics (Basel) · 2020 · PMC7763988 · PMID 33322819

Europe PMC DOI

hedged sentence

0.0460

closest p · 0.9× alpha

0.0460

boldest claim

The sentences

borderline significantp = 0.046actually significant

Compared to baseline, a borderline significant ( p = 0.046) increase in DCE-MR parameter v e was also found in responding lesions after 10 weeks.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.